REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Peptide Library

GHK-Cu

Copper Peptide / GHK-Copper / Copper Tripeptide-1

Recovery & Repair

GHK-Cu (Copper Peptide, Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine that declines significantly with age. First identified by Dr. Loren Pickart in 1973 from human albumin, it functions as a potent wound healing, anti-inflammatory, and tissue remodeling signal with demonstrated effects on gene expression affecting over 4,000 human genes. It is researched both as an injectable peptide and as a topical cosmeceutical ingredient for skin rejuvenation, hair growth, and collagen synthesis.

Mechanism of Action

Naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with copper(II). Activates tissue remodeling genes, promotes collagen synthesis, increases decorin and glycosaminoglycan production, and recruits stem cells to injury sites. Also suppresses TGF-beta to reduce scarring.

Research Protocols

For research purposes only. Not medical advice.

Topical: 1-2% concentration applied twice daily. Subcutaneous: 50-200mcg daily near target area. Research cycles of 4-8 weeks for injectable use. Topical use is ongoing.

Research Notes

Clinical Research Status

GHK-Cu has extensive in vitro and animal research spanning over 50 years, with numerous published studies on wound healing, skin remodeling, and gene expression modulation. Multiple topical formulations containing GHK-Cu are commercially available as cosmeceuticals, though injectable forms remain investigational. No FDA-approved drug product exists, but the compound has GRAS (Generally Recognized as Safe) status in topical applications.

Key Published Findings

Gene expression studies (Broad Institute Connectivity Map) demonstrate that GHK-Cu resets approximately 32% of human genes toward a pattern associated with younger tissue, including upregulation of collagen, decorin, and tissue inhibitors of metalloproteinases. Research shows it stimulates production of glycosaminoglycans, promotes angiogenesis, and recruits immune cells to wound sites. Published data confirm it increases fibroblast proliferation, collagen synthesis by up to 70%, and significantly accelerates wound contraction in animal models.

Safety Profile

GHK-Cu has an excellent safety profile in both topical and injectable applications, with no significant adverse effects reported in published literature. Plasma GHK levels in healthy young adults are approximately 200ng/mL, declining to ~80ng/mL by age 60, suggesting physiological familiarity. Topical concentrations of 1-4% are well-tolerated without irritation, and injectable doses used in research (1-5mg daily) have not produced notable adverse events.

Drug Interactions & Contraindications

Theoretical concern exists with Wilson's disease (copper storage disorder) or other conditions of copper overload, as the peptide delivers bioavailable copper. May interfere with copper chelation therapy (penicillamine, trientine). No significant drug interactions have been documented, though concurrent use with other copper supplements should be monitored.

Comparison to Related Compounds

Unlike synthetic growth factors (EGF, FGF) which target single pathways, GHK-Cu acts as a broad-spectrum tissue remodeling signal affecting thousands of genes simultaneously. Compared to retinoids for skin anti-aging, GHK-Cu produces collagen stimulation without the irritation, dryness, or photosensitivity. AHK-Cu (Alanyl-Histidyl-Lysine:Copper) is a related analog with similar but less-studied properties.

Community Observations

Injectable research protocols typically use 1-5mg subcutaneously daily or several times per week, often combined with BPC-157 or TB-500 for systemic tissue repair. Topical application (cream, serum) at 1-3% concentration is popular for facial rejuvenation, hair thinning, and scar reduction with visible results typically reported at 4-8 weeks. The peptide is notable for its dual utility as both an injectable research compound and a commercially available topical with legitimate cosmetic efficacy.

Half Life

~30-60 minutes

Reconstitution

Bacteriostatic water (BAC) for injection; aqueous solution for topical

Storage

Lyophilized

Refrigerate 2-8C up to 24 months.

Reconstituted

Refrigerate 2-8C. Use within 21 days.

US Legal Status

Research chemical (injectable) / Cosmetic ingredient (topical)

Also Known As

Copper PeptideGHK-CopperCopper Tripeptide-1

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer